BTK-IN-16

CAS No. 2883232-92-4

BTK-IN-16( —— )

Catalog No. M35437 CAS No. 2883232-92-4

BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 532 Get Quote
5MG 922 Get Quote
10MG 1140 Get Quote
25MG 1463 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BTK-IN-16
  • Note
    Research use only, not for human use.
  • Brief Description
    BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.
  • Description
    BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC50s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2883232-92-4
  • Formula Weight
    282.3
  • Molecular Formula
    C15H14N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N=1C=CC=C(C1)NC=2N=CN=C3C=C(OC)C(OC)=CC32
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kim T, et al. Two-Track Virtual Screening Approach to Identify the Dual Inhibitors of Wild Type and C481S Mutant of Bruton's Tyrosine Kinase. J Chem Inf Model. 2022 Aug 24.?
molnova catalog
related products
  • CGI-1746

    CGI-1746 is a potent, highly selective, second-generation BTK inhibitor with IC50 of 1.9 nM.

  • GNE-431

    GNE-431 is a potent, selective and noncovalent Btk inhibitor with IC50 of 3.2 nM and 2.5 nM for WT Btk and C481S mutant, respectively.

  • Atuzabrutinib

    Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.